Want to see HLN full AI Analyst Report?
HLN Stock Chart & Stats
$9.52
$0.04(0.37%)
At close: 4:00 PM EST
$9.52
$0.04(0.37%)
Day’s Range― - ―
52-Week Range$8.65 - $11.28
Previous CloseN/A
Volume6.87M
Average Volume (3M)9.21M
Market Cap
$44.24B
Enterprise Value$55.33K
Total Cash (Recent Filing)$1.32B
Total Debt (Recent Filing)$8.59B
Price to Earnings (P/E)20.1
Beta0.08
Next Earnings
Jul 30, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend Yield1.91%
Share Statistics
EPS (TTM)0.37
Shares Outstanding4,404,449,700
10 Day Avg. Volume6,886,400
30 Day Avg. Volume9,212,650
Financial Highlights & Ratios
PEG Ratio1.67
Price to Book (P/B)2.05
Price to Sales (P/S)3.05
P/FCF Ratio17.06
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$11.00Price Target Upside15.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.55
Revenue Forecast (FY)$15.17B
Bulls Say, Bears Say
Bulls Say
Improving MarginsSustained margin expansion reflects durable gains from supply‑chain and productivity programs, improving earnings quality and providing structural funding for marketing and R&D. Higher gross and net margins support cash generation and resilience even if top‑line growth remains modest.
Strong Cash GenerationHigh FCF conversion demonstrates that reported profits largely convert to cash, enabling reinvestment, deleveraging, or shareholder returns without reliance on external funding. The 2025 uplift shows capacity to fund transformation and working capital through operating cash flows.
Brand & Channel Strength (Oral Health)Leading brands in Oral Health, with targeted A&P, create durable competitive advantage in a defensive OTC category. Sensodyne’s sustained growth and focused investment underpin pricing power, share gains, and higher ROI on marketing, supporting long‑term category leadership.
Bears Say
Soft Revenue And VolumesTop‑line softness and below‑target volume trends limit the durability of margin gains and reduce operating leverage. If volume recovery lags, margins must fund growth investments and debt service, constraining sustainable revenue expansion and medium‑term return objectives.
Meaningful Debt LoadA structurally large debt stock reduces financial flexibility to invest behind brands or absorb shocks. Even with improving leverage, ongoing debt service and covenant considerations can constrain strategic options if organic growth underperforms or if cost savings underdeliver.
Seasonality & Channel Risk (U.S. Pharmacies)Dependence on seasonal categories and major pharmacy channels creates recurring demand volatility and exposure to retailer inventory cycles. Channel destocking or retailer changes can depress sell‑through and delay shelf gains, making growth recovery uneven across quarters and regions.
Haleon PLC Sponsored ADR News
HLN FAQ
What was Haleon PLC Sponsored ADR’s price range in the past 12 months?
Haleon PLC Sponsored ADR lowest stock price was $8.65 and its highest was $11.28 in the past 12 months.
What is Haleon PLC Sponsored ADR’s market cap?
Haleon PLC Sponsored ADR’s market cap is $44.24B.
When is Haleon PLC Sponsored ADR’s upcoming earnings report date?
Haleon PLC Sponsored ADR’s upcoming earnings report date is Jul 30, 2026 which is in 10 days.
How were Haleon PLC Sponsored ADR’s earnings last quarter?
Haleon PLC Sponsored ADR released its earnings results on Feb 25, 2026. The company reported $0.129 earnings per share for the quarter, beating the consensus estimate of $0.124 by $0.005.
Is Haleon PLC Sponsored ADR overvalued?
According to Wall Street analysts Haleon PLC Sponsored ADR’s price is currently Undervalued.
Does Haleon PLC Sponsored ADR pay dividends?
Haleon PLC Sponsored ADR pays a Quarterly dividend of $0.133 which represents an annual dividend yield of 1.91%. See more information on Haleon PLC Sponsored ADR dividends here
What is Haleon PLC Sponsored ADR’s EPS estimate?
Haleon PLC Sponsored ADR’s EPS estimate is 0.13.
How many shares outstanding does Haleon PLC Sponsored ADR have?
Haleon PLC Sponsored ADR has 4,404,449,700 shares outstanding.
What happened to Haleon PLC Sponsored ADR’s price movement after its last earnings report?
Haleon PLC Sponsored ADR reported an EPS of $0.129 in its last earnings report, beating expectations of $0.124. Following the earnings report the stock price went down -5.785%.
Which hedge fund is a major shareholder of Haleon PLC Sponsored ADR?
Currently, no hedge funds are holding shares in HLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haleon PLC Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (15.55% Upside)
$11.00 (15.55% Upside)
Blogger Sentiment
Neutral
HLN Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 4.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.26%
12-Months-Change
Fundamentals
Return on Equity
1.91%
Trailing 12-Months
Asset Growth
2.12%
Trailing 12-Months
Company Description
Haleon PLC Sponsored ADR
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
HLN Stock 12 Month Forecast
Average Price Target
$11.00
▲(15.55% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Perrigo Company
―
Teva Pharmaceutical
―
Takeda Pharmaceutical Company
―
Ownership Overview
―
Insiders
4.70% Mutual Funds
0.04% Other Institutional Investors
95.08% Public Companies and
Individual Investors